**Name of Journal:** *Artificial Intelligence in Gastroenterology*

**Manuscript NO:** 59601

**Manuscript Type:** MINIREVIEWS

**Artificial intelligence in gastrointestinal cancer: Recent advances and future perspectives**

Kudou M *et al*. AI in GI cancer

Michihiro Kudou, Toshiyuki Kosuga, Eigo Otsuji

**Michihiro Kudou, Toshiyuki Kosuga, Eigo Otsuji,** Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

**Michihiro Kudou,** Department of Surgery, Kyoto Okamoto Memorial Hospital, Kyoto 613-0034, Japan

**Toshiyuki Kosuga,** Department of Surgery, Saiseikai Shiga Hospital, Ritto 520-3046, Japan

**Author contributions:** Kudou M performed the research, analyzed the data, and wrote the manuscript; Kosuga T made contributions to conception and supervision of the study; Otsuji E critically revised the article; and all authors have read and approved the final manuscript.

**Corresponding author: Toshiyuki Kosuga, MD, PhD, Assistant Professor,** Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. toti-k@koto.kpu-m.ac.jp

**Received:** September 19, 2020

**Revised:** October 28, 2020

**Accepted:** November 13, 2020

**Published online:** November 28, 2020

**Abstract**

Artificial intelligence (AI) using machine or deep learning algorithms is attracting increasing attention because of its more accurate image recognition ability and prediction performance than human-aid analyses. The application of AI models to gastrointestinal (GI) clinical oncology has been investigated for the past decade. AI has the capacity to automatically detect and diagnose GI tumors with similar diagnostic accuracy to expert clinicians. AI may also predict malignant potential, such as tumor histology, metastasis, patient survival, resistance to cancer treatments and the molecular biology of tumors, through image analyses of radiological or pathological imaging data using complex deep learning models beyond human cognition. The introduction of AI-assisted diagnostic systems into clinical settings is expected in the near future. However, limitations associated with the evaluation of GI tumors by AI models have yet to be resolved. Recent studies on AI-assisted diagnostic models of gastric and colorectal cancers in the endoscopic, pathological, and radiological fields were herein reviewed. The limitations and future perspectives for the application of AI systems in clinical settings have also been discussed. With the establishment of a multidisciplinary team containing AI experts in each medical institution and prospective studies, AI-assisted medical systems will become a promising tool for GI cancer.

**Key Words:** Artificial intelligence; Gastric cancer; Colorectal cancer; Endoscopy; Pathology; Radiology

Kudou M, Kosuga T, Otsuji E. Artificial intelligence in gastrointestinal cancer: Recent advances and future perspectives. *Artif Intell Gastroenterol* 2020; 1(4): 71-85 URL: https://www.wjgnet.com/2644-3236/full/v1/i4/71.htm DOI: https://dx.doi.org/10.35712/aig.v1.i4.71

**Core Tip:** Artificial intelligence (AI) is attracting increasing attention because of its more accurate image recognition ability and prediction performance than human-aid analyses. The application of AI models to gastrointestinal clinical oncology has been investigated, and the findings obtained indicate its capacity for automatic diagnoses with similar accuracy to expert clinicians and the prediction of malignant potential. However, limitations in the evaluation of gastrointestinal tumors by current AI models have yet to be resolved. The limitations of and future perspectives for the application of AI-assisted systems to clinical settings have been discussed herein.

**INTRODUCTION**

Recent advances in diagnostic technology and treatment strategies for gastrointestinal cancer have improved clinical outcomes. Even with the development of novel imaging modalities with high accuracy and resolution, image reading, and novel biomarkers, such as the genetic screening of tumors, circulating tumor DNA, and micro RNA, the diversity and quantity of data on tumor malignant potential is beyond the limits of human interpretation[1-8]. Therefore, the establishment of more accurate diagnostic methods with high objectivity using computer-aided diagnosis systems (CAD), such as technologies involving artificial intelligence (AI), is needed in clinical settings[9-11].

AI is defined by the intelligence of machines in contrast to the natural intelligence of humans. It is generally applied when a machine mimics the cognitive functions of humans, such as learning and problem solving[12]. The concept of AI was initially advocated in 1956 by McCarthy *et al*[13], and the development of machines with the ability to think like humans with intelligence was anticipated. However, machines or computer programs that function as classifiers or detectors, such as image classification and recognition and the prediction of characteristics in populations, are currently regarded as AI.

Recent AI technologies were developed due to technical advances in machine learning and deep neural network algorithms[14-17]. Convolutional neural networks (CNN) are one of the deep neural networks that are useful for image analyses. Algorithms using CNN models have been applied to many research fields in gastrointestinal cancer, such as the automatic endoscopic detection of tumors, the automatic diagnosis of cancer in pathological specimens, and image analyses of radiological modalities[10,18]. In endoscopic research, CNN are trained using thousands of endoscopic images to detect tumors, differentiate between benign and malignant tumors, and predict tumor invasion depth[9,19-22]. In recent years, a real-time CAD endoscopic system was developed using trained CNN. In the area of pathology, deep learning has been performed using non-cancerous and cancer images to automatically identify and segment the cytoplasm, nucleus, and stromal cells. CNN and machine learning models with image analyses, such as a texture analysis, were subsequently built to identify cancerous regions or diagnose cancer[23]. In the field of radiology, a CAD system of image modalities, such as X-ray, computed tomography (CT), and magnetic resonance images (MRI), was developed using a deep learning model constructed using cancer and non-cancer images to recognize anatomy and detect and segment tumors[24]. The malignant potential of tumors has been analyzed using a radiomics approach, which aims to quantitatively assess tumor heterogeneity by an analysis of medical images through the deep or machine learning of histograms, textures, and shapes[25-27]. AI models of gastrointestinal cancer are summarized in Figure 1.

AI with strong analytical power has attracted the attention of many researchers; therefore, the number of studies on diagnostic AI systems in gastrointestinal cancer has rapidly increased in the past decade. We herein investigate recent advances and future perspectives through a review of the literature.

In this minireview, the bibliographic search was performed using the database MEDLINE (through PubMed) for identifying studies published on AI technology in the endoscopy, pathology, and radiology of gastric and colorectal cancer between 2016 and 2020. We summarized the application of AI in each area according to the extracted 49 Literatures; subsequently, the consideration about current issues and future perspectives of AI in gastrointestinal cancer was stated with some literature review.

**Application of AI to endoscopy in gastrointestinal cancer**

Previous studies on the endoscopic diagnosis of gastric cancer (GC) and colorectal cancer (CRC) using AI between 2016 and 2020 were summarized in Tables 1 and 2.

***Gastric cancer***

The purposes of the studies reviewed on AI for GC were (1) tumor detection; (2) the diagnosis of malignancy; (3) real-time detection; and (4) the prediction of tumor invasion depth. The basic method of these studies was as follows: endoscopic images of GC, gastritis, and non-cancerous mucosae, which were diagnosed pathologically or by an expert endoscopist, were captured and CNN was subsequently trained using these images. Diagnostic and detection accuracy were then assessed using the constructed CNN models.

Yoon *et al*[28] attempted to develop CNN models with the ability to detect early GC and predict invasion depth. The areas under the curves of receiver operating characteristic curves (AUC) for early GC detection and depth prediction were 0.981 and 0.851, respectively. Moreover, the diagnostic accuracy of invasion depth was lower for undifferentiated GC than for differentiated GC[28]. Zhu *et al*[29] also trained a CNN model to predict the invasion depth of GC. The AUC, positive predictive value (PPV), and negative predictive value (NPV) of their model were 0.94, 89.6%, and 88.9%, respectively. The CNN-CAD system achieved significantly higher accuracy and specificity than a human endoscopist. Li *et al*[30] also developed CNN models for the detection of GC with high diagnostic accuracy (sensitivity: 91.1%, specificity: 90.6%, and PPV: 90.9%). Hirasawa *et al*[31] reported that CNN models exhibited difficulties distinguishing between differentiated-type intramucosal cancers with a diameter of 6 mm or less and gastritis. Ishioka *et al*[32]examined the detection accuracy of a real-time endoscopic diagnosis of GC using CNN models that they had constructed; the detection rate of GC using these models was 94.1%. CNN identified the region of GC that had been difficult to distinguish from background gastritis, even by experienced endoscopists. Luo *et al*[33]developed a gastrointestinal AI diagnostic system (GRAIDs) and compared its diagnostic accuracy with that of expert and trainee endoscopists. PPV was 0.814 for GRAIDs, 0.932 for the expert endoscopist, and 0.824 for the trainee endoscopist, while NPV was 0.978 for GRAIDs, 0.980 for the expert endoscopist, and 0.904 for the trainee endoscopist. These findings demonstrated that the diagnostic accuracy of GRAIDs for the detection of GC was similar to that of the expert endoscopist and superior to that of the trainee endoscopist. CNN models of narrow-band imaging (NBI) for GC have been reported, with sensitivity and PPV of 91.1-95.4% and 82.3-90.6%, respectively[34].

***Colorectal cancer***

The purposes of the studies reviewed on AI for CRC were (1) the segmentation and detection of polyps; and (2) the diagnosis of polyp pathology. In the development of efficient automatic diagnostic models, models need to automatically segment polyps and extract their features. Akbari *et al*[35]attempted to construct CNN models of colonoscopy for automatic segmentation and feature extraction. The accuracy, specificity, and sensitivity of the model for automatic segmentation were 0.977, 0.993, and 0.758, respectively. An ideal CAD system of colonoscopy needs to have the ability to predict the pathological diagnosis of an automatically detected tumor and subsequently recommend appropriate treatment strategies for lesions. Jin *et al*[36]reported a CNN model for predicting the pathological diagnosis of small lesions (≤ 5 mm) using NBI data from colonoscopy. The accuracy, sensitivity, specificity, PPV, and NPV of their model for predicting the pathological diagnosis of polyps, adenoma *vs* hyperplasia were 86.7%, 83.3%, 91.7%, 93.8%, and 78.6%, respectively. On the other hand, the accuracies of polyp diagnoses by novices, experts, and NBI-trained expert endoscopists were 73.8%, 83.8%, and 87.6%, respectively. Using CNN-processed results, overall accuracy by novice endoscopists significantly increased to 85.6%. A real-time diagnostic system in colonoscopy was developed using CNN models. Urban *et al*[37] constructed CNN models to identify polyps, which were subsequently adapted to colonoscopy videos, and these models exhibited the ability to detect either type of polyp equally well and identify polyps with an ROC value of 0.991 and accuracy of 96.4%. Yamada *et al*[38]applied their CNN model, which was developed to detect early signs of CRC, to colonoscopic videos. The sensitivity and specificity of their AI system for detecting the regions of CRC were 97.3% and 99.0%, respectively, while the sensitivity and specificity of endoscopists were 87.4% and 96.4%; respectively. Therefore, the AI system may be used to alert endoscopists in real-time to overlooked abnormalities, such as non-polypoid polyps, during colonoscopy, thereby increasing the early detection of this disease.

**Applications of AI to THE pathological diagnosis OF GASTROINTESTINAL CANCER**

Previous studies on the pathological diagnosis of GC and CRC using AI between 2016 and 2020 are summarized in Tables 3 and 4. An automatic pathological diagnosis of gastrointestinal cancer generally involves the following processes: (1) automatic segmentation: distinguishing various structures, such as the cytoplasm, nuclei, and stoma, and the recognition of atypia; (2) the diagnosis and grading of carcinoma; (3) the diagnosis of malignant potential, such as invasion depth and lymphovascular invasion; and (4) the prediction of survival. Therefore, previous studies aimed to develop a CAD system with the ability to perform these processes.

***Gastric cancer***

Qu *at al*[39] attempted to develop CNN models for (1) and (2), proposed a novel stepwise fine-tuning-based deep learning scheme for gastric pathology image classification, and established a novel protocol to further boost the performance of state-of-the-art deep neural networks and overcome the insufficiency of well-annotated data. In their proposed two-stage method, CNN was initially trained using tissue-wise data on the background, epithelium, and stoma as well as cell-wise data on nuclei and the cytoplasm, and was then tuned using well-annotated data from benign or malignant data sets. The diagnostic accuracy of their constructed two-stage CNN models was higher than that of one-stage models. Yoshida *et al*[40] attempted to develop CNN models for (1) and (2) with the ability to automatically segment malignant regions in full-slide images of biopsy samples and subsequently diagnose histological classifications through a nuclear analysis at high magnification. In negative biopsy specimens, the concordance rate between their AI system and expert pathologists was 90.6%; however, the concordance rate for positive biopsy specimens was less than 50%. Mori *et al*[41]trained CNN models for (3) to discriminate the tumor invasion depth of gastric signet-ring cell carcinoma. Their models exhibited the ability to diagnose intramucosal or advanced histological characteristics with an accuracy of 85%, sensitivity of 90%, specificity of 81%, and AUC of 0.91. The prediction of survival in GC patients using the deep learning method has also been examined. Jiang *et al*[42] investigated the efficacy of deep learning models for (4) using a support vector machine (SVM). They classified GC patients into two groups using SVM based on patient characteristics and immunohistochemistry (IHC) data on the following immunomarkers: CD3, CD8, CD45RO, CD45RA, CD57, CD68, CD66b, and CD34. The findings obtained revealed that the classifier of SVM was a stronger prognostic factor than the TNM stage or CA19-9.

***Colorectal cancer***

Numerous studies on the pathology of CRC using AI were reported compared to GC, are classified as follows.

**Studies on AI models for automatic segmentation:** Van Eycke *et al*[43] and Graham *et al*[44] developed CNN models to segment the glandular epithelium. The F1 values of these models ranged between 0.9 and 0.912. Abdelsamea *et al*[45]developed tumor parcellation and quantification (TuPaQ), which is a tool for refining biomarker analyses through the rapid and automated segmentation of the tumor epithelium. Tissue microarray (TMA) cores from CRC were manually annotated and analyzed to provide the ground truth, epithelial or non-epithelial tissue. CNN (TuPaQ) was trained using these data. The accuracy, sensitivity, and specificity of TuPaQ were 0.939, 0.779, and 0.946, respectively. Yan *et al*[46] examined the diagnostic accuracy of their AI models for the classification, segmentation, and visualization of large-scale tissue histopathology images. The accuracies of their models ranged between 81.3 and 93.2%. Haj-Hassan *et al*[47] attempted to develop CNN models for the automatic segmentation of benign hyperplasia, intra-epithelial neoplasms, and carcinoma, and the findings obtained showed that the models segmented tumors with a high accuracy of 99.1%.

**Diagnosis and grading of carcinoma:** Rathore *et al*[48] reported deep learning models for cancer detection and grading. The features of CRC biopsy samples were extracted based on pink-colored connecting tissues, purple-colored nuclei, and white-colored epithelial cells and lumina. The extracted features, particularly white-colored epithelial cells and lumina, were classified using SVM and classification performance was subsequently assessed. The accuracies of cancer detection and grading by their model were 95.4 and 93.4%, respectively. Yang *et al*[49] proposed a combination of SVM and color histograms to classify pathological images. The AUC of the model for diagnosing carcinoma was 0.891. Chaddad *et al*[50]reported that the classification of images using a texture analysis effectively diagnosed carcinoma (accuracy: 98.9%). Yoshida *et al*[51] showed that a CAD system using a previously described CNN model for GC was useful for diagnosing adenoma and carcinoma (undetected rate of carcinoma and adenoma: 0-9.3% and 0-9.9%, respectively).

**Diagnosis of malignant potential:** Takamatsu *et al*[52] reported the prediction of lymph node metastasis using a machine learning analysis of morphological parameters (such as shape and roundness) in cytokeratin-stained T1 CRC images. The AUC of the model was 0.94. The automatic evaluation of tumor budding in IHC with CNN and machine learning was previously performed[53]. Models were constructed to assess tumor budding using TMA on pan-cytokeratin-stained tumors, and the *R*2 value of the correlation of the models with manual counting for the diagnosis of tumor budding was 0.86.

**Prediction of survival:** Bychkov *et al*[54] proposed AI models for the automatic prediction of survival in CRC patients using the TMA of CRC pathological images. The automatic detection of tumors was initially achieved using CNN; CNN cases were subsequently classified by a recurrent neural network. Predicted survival by their model correlated with actual clinical outcomes. Kather *et al*[55] reported automatic models for discriminating structures in tissue samples and then predicting survival. Their models predicted the survival of CRC more accurately than the TNM stage or manual evaluations of cancer-associated fibroblasts. Moreover, survival prediction SVM models using immunomarkers evaluated by IHC, such as CD3 and CD8, have been developed[56], and the classifier correlated with patient survival.

**Applications of AI to A radiological diagnosis OF gastrointestinal cancer**

Previous studies on the radiological diagnosis of GC and CRC using AI between 2016 and 2020 were summarized in Tables 5 and 6.

***Gastric cancer***

Regarding GC, many researchers have attempted to develop AI models using (1) a radiomics approach; or (2) CNN models predicted malignant potential, such as survival, lymph node metastasis, and post-operative recurrence, through analyses of the radiological image features of GC.

**Radiomics approach:** Li *et al*[57] developed a survival prediction model involving a general radiomics analysis of CT. The region of interest was manually drawn along the margin of the tumor on CT images, and radiological features were extracted. After manual image segmentation, the heterogeneity of the extracted feature was quantified using an image analysis, such as texture and histogram analyses. Analyzed cases were then classified based on the risk score (R-signature) evaluated using the least absolute shrinkage and selection operator method. The performance of a radiomics nomogram, including factors correlating with survival, was then evaluated. The findings obtained showed that the R-signature correlated with the survival of GC patients. Furthermore, the prediction of survival by the radiomics monogram including the R-signature was more accurate than that by normal nomograms (T and N stages and differentiation). Previous studies investigated the prediction of malignant potential using a radiomics approach. Zhang *et al*[58]evaluated the diagnostic accuracy of CT radiomics models for predicting post-operative recurrence in GC patients, and the AUC of the models were 0.806-0.831. Li *et al*[59] reported CT radiomics models for predicting lymph node metastasis, with an AUC of 0.82-0.84. Li *et al*[60] also developed CT radiomic models with the ability to predict the pathological status and survival with high accuracy. Wang *et al*[61] analyzed primary tumors on CT images of the arterial phase, portal phase, and delay phase for the discrimination of intestinal-type GC by a radiomics approach. The AUC of their model was 0.904. Jiang *et al*[62] described a radiomics model of PET-CT for predicting survival. The C-indexes of this model for overall survival and disease-free survival were 0.786 and 0.800, respectively. A radiomics analysis of MRI for GC has also been conducted. Chen *et al*[63] examined the heterogeneity of primary tumors on MRI using a radiomics approach, and showed that the model was useful for predicting the N stage.

**CNN model:** Gao *et al*[64] developed a CNN model of CT for predicting lymph node metastasis. Radiologists initially labeled upper abdominal-enhanced CT images of metastatic lymph nodes. CNN models were then constructed using the labeled image data, and the AUC of the model was 0.954. Huang *et al*[65] described a protocol for predicting peritoneal metastasis using CNN models, and this research is ongoing.

***Colorectal cancer***

Treatment strategies for lower rectal cancer (LRC) have recently been attracting increasing attention because of the difficulties associated with achieving curative treatment. Therefore, many researchers have targeted LRC patients for the development of AI models for radiological diagnoses. The aims of a recent AI study on CRC were (1) the automatic detection or segmentation of primary tumors; (2) the prediction of treatment responses; and (3) the prediction of malignant potential.

**Automatic detection or segmentation of primary tumors:** Trebeschi *et al*[66] reported a CNN model for the automatic segmentation of primary tumors on MRI. CNN models were trained using T2-weighted images (T2WI) and diffusion-weighted images with primary tumor labeling by expert radiologists. The CNN model showed high segmentation accuracy, with a dice similarity coefficient (DSC) of 0.68-0.70. The AUC of the resulting probability maps was 0.99. Two CNN models were also developed for the automatic segmentation of primary tumors on T2WIs, with DSC of 0.82 and 0.74, respectively[67,68]. Men *et al*[69] attempted to develop CNN models for automatic segmentation on CT images with an application to the delineation of the clinical target volume (CTV) and surrounding organs for radiotherapy. The mean DSC values of the models were 87.7% for the CTV, 93.4% for the bladder, 92.1% for the left femoral head, 92.3% for the right femoral head, 65.3% for the intestines, and 61.8% for the colon.

**Prediction of treatment responses:** Shayesteh *et al*[70]reported radiomics models predicting treatment responses to neo-adjuvant chemoradiotherapy. Primary tumors on MRI T2WI were manually segmented and an image analysis of the data, shape, texture as well as a histogram analysis were performed. The relationship between the pathological features and treatment responses to CRT was assessed by a machine learning approach, which revealed that the AUC and accuracy of the model were 95 and 90%, respectively. Shi *et al*[71] and Ferrari *et al*[72] also described the efficacy of radiomics models for predicting CRT responses using pre-treatment, mid-radiation, post-treatment MRI (AUC for predicting a complete response (CR): 0.83 and 0.86, respectively). Bibault *et al*[73]compared the diagnostic accuracy of several models, Cox’s regression, CNN, and SVM for predicting CR in pre-operative CRT using CT data. CNN exhibited the ability to predict CR with the highest accuracy (80%). A radiomics model for predicting chemotherapeutic responses has also been reported. Dercle *et al*[74] demonstrated that their radiomic model using CT images successfully predicted sensitivity to anti-EGFR therapy (AUC: 0.80).

**Prediction of malignant potential:** Ding *et al*[75]developed AI models to predict lymphatic node metastasis using pre-operative MRI. CNN models were constructed using MRI lymph node images manually labeled by radiologists. They compared the diagnostic accuracy of CNN and a radiologist for predicting lymph node metastasis. As a result, CNN was more accurate than radiologists in identifying pelvic metastatic lymph nodes. A model for predicting gene profiles was also reported. These research methods are generally called radiogenomics. Taguchi *et al*[76] showed that a machine learning model using a texture analysis of CT images and SUV values of PET-CT predicted KRAS mutations with high accuracy (AUC: 0.82).

**Current issueS and future perspectives**

***AI research for endoscopy***

The majority of studies previously reported that a CAD system using AI for endoscopy had the ability to diagnose gastrointestinal tumors with high accuracy; however, there were many limitations. Researchers were more likely to use high-quality endoscopic images to construct AI models, which cannot always be acquired in clinical settings[9]. Furthermore, outcome indicators for clinical applications have not yet been defined. Therefore, parameters to assess the functional performance of AI models need to be established[19]. In addition, the majority of studies have been retrospective in nature using still images from non-clinical settings. These conditions do not mimic real-time clinical settings, in which endoscopists often encounter difficult-to-analyze images in daily practice. Moreover, it currently remains unclear whether AI models will enhance medical performance, reduce medical costs, and increase the satisfaction of patients and medical staff in clinical settings. Another limitation is that many clinicians and clinical researchers do not have sufficient knowledge to understand AI systems; therefore, non-AI experts as well as medical journal reviewers may encounter difficulties when assessing research on AI and its applications. Furthermore, the number of medical staff with the skill to educate physicians on AI is very limited[19].

Nevertheless, once these limitations are resolved, CAD systems using AI will markedly improve diagnostic quality in endoscopic examinations. CAD systems for endoscopy are expected to serve as a second observer during real-time endoscopy, facilitating the detection of more neoplasms by endoscopists. Some CAD systems may also provide “optical biopsies” to differentiate the types of colon polyps[9]. Therefore, CAD systems have a promising future in the effective training of junior endoscopists as assistant observers.

***AI research for pathology***

Previous studies reported that AI models distinguish structures in tissues and detect cancerous regions with high accuracy. Furthermore, survival may be predicted using image analyses by AI. However, there are also a number of limitations in research. AI models are educated using pathological images of cancer tissue labeled by pathologists. However, interobserver disagreement in pathological diagnoses commonly occurs between pathologists[77,78]. Therefore, the quality of teaching data varied in each study. Furthermore, the majority of AI models were constructed using a small cohort. It might be possibility non-reproducible laboratory-specific machine learning methods. In addition, the clinical use of AI models requires a digital slide scanner, image storage, maintenance contracts, image analysis software, and IT support systems, which may be expensive in clinical settings. Moreover, many pathologists and technicians do not have sufficient knowledge to understand AI systems. Therefore, the recruitment of AI experts to introduce AI systems into clinical settings is needed for education and the adjustment of systems to different clinical settings.

Despite these limitations, whole-slide scanning using AI models, such as the TMA method, is advantageous for pathologists and clinicians. This method may be a second observer in the prevention of false diagnoses by pathologists and the teaching of trainees. Furthermore, the heterogeneities of cancer tissue cannot be precisely evaluated by the human eyes of pathologists. Therefore, the assessment of cancer tissue using AI models is a novel research method beyond human cognition that is expected to predict proteomics, genomics, and the molecular signaling pathways of tumors as precision medicine by cancer genome sequencing.

***AI research for radiology***

Previous studies reported the efficacy of automatic segmentation or diagnosis in solid malignant tumors[77-79]. However, difficulties are associated with automatic segmentation by AI models in the field of gastrointestinal cancer because of large individual differences in imaging features of the gastrointestinal tract, except for the rectum. The radiomics approach represents an attractive method for detecting malignant potential and imaging biomarkers for precision medicine through image analyses of intratumor heterogeneity. However, a number of limitations need to be considered. The manual or semi-automatic segmentation of tumors is generally needed in the radiomics approach. Interobserver variability in manual segmentation often occurs in this process, resulting in the poor reproducibility of data by the radiomics model. Furthermore, previous studies demonstrated that radiomic features may be affected by a number of parameters, such as the scanning equipment[80], image pre-processing[81], acquisition protocols[82,83], image reconstruction algorithms[84,85], and delineation. In addition, although researchers of radiology or AI experts are knowledgeable about radiomics and AI models, they often cannot target the clinical task that needs to be improved for clinicians or patients in clinical settings. However, clinicians are not sufficiently aware of AI, and few reviewers of scientific literature on clinical medicine often are developing AI models or are able to judge research involving AI. Therefore, a multidisciplinary team needs to be introduced into research and medical teams to promote AI-supported medicine.

Despite these limitations, radiomic models for the image diagnosis or prediction of malignancy have the potential to support clinical teams for more accurate and rapid diagnoses. These models may increase patient satisfaction levels for homogenized diagnostic accuracy. Moreover, radiogenomics may have a major impact on precision medicine. Non-invasive assessments of the entire tumor tissue may be possible, without having to rely on a single biopsy to represent all cancer lesions within a patient. As further information becomes available on these imaging markers, the characteristics of cancers will be elucidated in more detail. Therefore, the radiomics approach will enhance the treatment effects of molecular biological approaches for oncological precision medicine.

**DiSCUSSION**

AI will be an important component of diagnostic methods to diagnosis patient disease, determine most appropriate treatments, and predict prognosis and drug resistance. A lot of research methods have been developed with the aims and found to have varying levels of performance. For clinical use of disease diagnosis, AI seems valuable for use in endoscopy, where it could increase detection of benign polyp and malignant tumor. Meanwhile, AI may be useful to analysis intratumor heterogeneity of radiological and pathological images in order to predict malignant potentials, such as the prognosis of patients and therapeutic effects. Our minireview covered only articles listed in MEDLINE, and might have missed some literatures in medical image analysis journals and computer science. Despite of the limitation, AI has become an important part of clinical cancer research in recent years.

There is no turning back for the development of AI in gastrointestinal cancer, and future implications are large. However, some limitations that require caution should be recognized. Most studies were performed using low-quality datasets from pre-clinical studies. Furthermore, AL algorithms are often considered to be black-box models. The difficulty in understanding the process of AI decision may prevent physicians from finding the potential confounding factors. Ethical challenge is one of the problems to be considered. In the present AI system, AI is not aware of the human preferences or legal liabilities. Therefore, medical staff will have to make decisions for patients according to their preferences, environment, and ethics. AI will not completely replace doctors, and computer technology and medical staff will always have to work together. However, the diagnostic accuracy of AI systems has markedly increased and may detect novel biomarkers that cannot be identified by the human eye or in human-aid analyses. AI systems will be introduced into general hospitals in the near future under the management of multidisciplinary teams consisting of medical staff and AI experts.

**CONCLUSION**

We reviewed the recent published literatures on AI in gastrointestinal cancer, suggesting that AI may be used to accurately diagnose clinical images, identify new therapeutic targets, and process clinical data from large patient datasets. Although the physicians must recognize the limitations of AI diagnostic system, AI-assisted medical systems will become a promising tool for gastrointestinal cancer.

**REFERENCES**

1 **Huynh JC**, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. *Cancers (Basel)* 2020; **12**: [PMID: 32384640 DOI: 10.3390/cancers12051168]

2 **Huang RJ**, Choi AY, Truong CD, Yeh MM, Hwang JH. Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions. *Gut Liver* 2019; **13**: 596-603 [PMID: 31394893 DOI: 10.5009/gnl19181]

3 **Tsujiura M**, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E. Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2014; **20**: 3265-3286 [PMID: 24696609 DOI: 10.3748/wjg.v20.i12.3265]

4 **Okajima W**, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2017; **23**: 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650]

5 **Imamura T**, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2016; **22**: 5627-5641 [PMID: 27433079 DOI: 10.3748/wjg.v22.i25.5627]

6 **Lech G**, Słotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. *World J Gastroenterol* 2016; **22**: 1745-1755 [PMID: 26855534 DOI: 10.3748/wjg.v22.i5.1745]

7 **Li TT**, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. *World J Gastroenterol* 2018; **24**: 2236-2246 [PMID: 29881233 DOI: 10.3748/wjg.v24.i21.2236]

8 **Van Cutsem E**, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T. Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. *Cancers (Basel)* 2016; **8**: [PMID: 27589804 DOI: 10.3390/cancers8090081]

9 **He YS**, Su JR, Li Z, Zuo XL, Li YQ. Application of artificial intelligence in gastrointestinal endoscopy. *J Dig Dis* 2019; **20**: 623-630 [PMID: 31639272 DOI: 10.1111/1751-2980.12827]

10 **Le Berre C**, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. *Gastroenterology* 2020; **158**: 76-94.e2 [PMID: 31593701 DOI: 10.1053/j.gastro.2019.08.058]

11 **Que SJ**, Chen QY, Qing-Zhong, Liu ZY, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Li P, Zheng CH, Huang CM, Xie JW. Application of preoperative artificial neural network based on blood biomarkers and clinicopathological parameters for predicting long-term survival of patients with gastric cancer. *World J Gastroenterol* 2019; **25**: 6451-6464 [PMID: 31798281 DOI: 10.3748/wjg.v25.i43.6451]

12 **Stuart JR,** Peter N. Artificial intelligence a modern approach, 3rd Edition. Pearson Education, 2009

13 **McCarthy J,** Minsky ML, Rochester N, Shannon CE. A proposal for the dartmouth summer research project on artificial intelligence. *Dartmouth Proposal* 1955: 1-13

14 **Deo RC**. Machine Learning in Medicine. *Circulation* 2015; **132**: 1920-1930 [PMID: 26572668 DOI: 10.1161/CIRCULATIONAHA.115.001593]

15 **LeCun Y**, Bengio Y, Hinton G. Deep learning. *Nature* 2015; **521**: 436-444 [PMID: 26017442 DOI: 10.1038/nature14539]

16 **Erickson BJ**, Korfiatis P, Akkus Z, Kline TL. Machine Learning for Medical Imaging. *Radiographics* 2017; **37**: 505-515 [PMID: 28212054 DOI: 10.1148/rg.2017160130]

17 **McBee MP**, Awan OA, Colucci AT, Ghobadi CW, Kadom N, Kansagra AP, Tridandapani S, Auffermann WF. Deep Learning in Radiology. *Acad Radiol* 2018; **25**: 1472-1480 [PMID: 29606338 DOI: 10.1016/j.acra.2018.02.018]

18 **Yang YJ**, Bang CS. Application of artificial intelligence in gastroenterology. *World J Gastroenterol* 2019; **25**: 1666-1683 [PMID: 31011253 DOI: 10.3748/wjg.v25.i14.1666]

19 **Min JK**, Kwak MS, Cha JM. Overview of Deep Learning in Gastrointestinal Endoscopy. *Gut Liver* 2019; **13**: 388-393 [PMID: 30630221 DOI: 10.5009/gnl18384]

20 **Mori Y**, Kudo SE, Mohmed HEN, Misawa M, Ogata N, Itoh H, Oda M, Mori K. Artificial intelligence and upper gastrointestinal endoscopy: Current status and future perspective. *Dig Endosc* 2019; **31**: 378-388 [PMID: 30549317 DOI: 10.1111/den.13317]

21 **Ebigbo A**, Palm C, Probst A, Mendel R, Manzeneder J, Prinz F, de Souza LA, Papa JP, Siersema P, Messmann H. A technical review of artificial intelligence as applied to gastrointestinal endoscopy: clarifying the terminology. *Endosc Int Open* 2019; **7**: E1616-E1623 [PMID: 31788542 DOI: 10.1055/a-1010-5705]

22 **Ahmad OF**, Soares AS, Mazomenos E, Brandao P, Vega R, Seward E, Stoyanov D, Chand M, Lovat LB. Artificial intelligence and computer-aided diagnosis in colonoscopy: current evidence and future directions. *Lancet Gastroenterol Hepatol* 2019; **4**: 71-80 [PMID: 30527583 DOI: 10.1016/s2468-1253(18)30282-6]

23 **Acs B**, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med* 2020; **288**: 62-81 [PMID: 32128929 DOI: 10.1111/joim.13030]

24 **Bi WL**, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH, Tamimi RM, Tempany CM, Swanton C, Hoffmann U, Schwartz LH, Gillies RJ, Huang RY, Aerts HJWL. Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA Cancer J Clin* 2019; **69**: 127-157 [PMID: 30720861 DOI: 10.3322/caac.21552]

25 **Mayerhoefer ME**, Materka A, Langs G, Häggström I, Szczypiński P, Gibbs P, Cook G. Introduction to Radiomics. *J Nucl Med* 2020; **61**: 488-495 [PMID: 32060219 DOI: 10.2967/jnumed.118.222893]

26 **Forghani R**, Savadjiev P, Chatterjee A, Muthukrishnan N, Reinhold C, Forghani B. Radiomics and Artificial Intelligence for Biomarker and Prediction Model Development in Oncology. *Comput Struct Biotechnol J* 2019; **17**: 995-1008 [PMID: 31388413 DOI: 10.1016/j.csbj.2019.07.001]

27 **Bibault JE**, Xing L, Giraud P, El Ayachy R, Giraud N, Decazes P, Burgun A, Giraud P. Radiomics: A primer for the radiation oncologist. *Cancer Radiother* 2020; **24**: 403-410 [PMID: 32265157 DOI: 10.1016/j.canrad.2020.01.011]

28 **Yoon HJ**, Kim S, Kim JH, Keum JS, Oh SI, Jo J, Chun J, Youn YH, Park H, Kwon IG, Choi SH, Noh SH. A Lesion-Based Convolutional Neural Network Improves Endoscopic Detection and Depth Prediction of Early Gastric Cancer. *J Clin Med* 2019; **8**: [PMID: 31454949 DOI: 10.3390/jcm8091310]

29 **Zhu Y**, Wang QC, Xu MD, Zhang Z, Cheng J, Zhong YS, Zhang YQ, Chen WF, Yao LQ, Zhou PH, Li QL. Application of convolutional neural network in the diagnosis of the invasion depth of gastric cancer based on conventional endoscopy. *Gastrointest Endosc* 2019; **89**: 806-815.e1 [PMID: 30452913 DOI: 10.1016/j.gie.2018.11.011]

30 **Li L**, Chen Y, Shen Z, Zhang X, Sang J, Ding Y, Yang X, Li J, Chen M, Jin C, Chen C, Yu C. Convolutional neural network for the diagnosis of early gastric cancer based on magnifying narrow band imaging. *Gastric Cancer* 2020; **23**: 126-132 [PMID: 31332619 DOI: 10.1007/s10120-019-00992-2]

31 **Hirasawa T**, Aoyama K, Tanimoto T, Ishihara S, Shichijo S, Ozawa T, Ohnishi T, Fujishiro M, Matsuo K, Fujisaki J, Tada T. Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. *Gastric Cancer* 2018; **21**: 653-660 [PMID: 29335825 DOI: 10.1007/s10120-018-0793-2]

32 **Ishioka M**, Hirasawa T, Tada T. Detecting gastric cancer from video images using convolutional neural networks. *Dig Endosc* 2019; **31**: e34-e35 [PMID: 30449050 DOI: 10.1111/den.13306]

33 **Luo H**, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. *Lancet Oncol* 2019; **20**: 1645-1654 [PMID: 31591062 DOI: 10.1016/s1470-2045(19)30637-0]

34 **Horiuchi Y**, Aoyama K, Tokai Y, Hirasawa T, Yoshimizu S, Ishiyama A, Yoshio T, Tsuchida T, Fujisaki J, Tada T. Convolutional Neural Network for Differentiating Gastric Cancer from Gastritis Using Magnified Endoscopy with Narrow Band Imaging. *Dig Dis Sci* 2020; **65**: 1355-1363 [PMID: 31584138 DOI: 10.1007/s10620-019-05862-6]

35 **Akbari M**, Mohrekesh M, Nasr-Esfahani E, Soroushmehr SMR, Karimi N, Samavi S, Najarian K. Polyp Segmentation in Colonoscopy Images Using Fully Convolutional Network. *Annu Int Conf IEEE Eng Med Biol Soc* 2018; **2018**: 69-72 [PMID: 30440343 DOI: 10.1109/EMBC.2018.8512197]

36 **Jin EH**, Lee D, Bae JH, Kang HY, Kwak MS, Seo JY, Yang JI, Yang SY, Lim SH, Yim JY, Lim JH, Chung GE, Chung SJ, Choi JM, Han YM, Kang SJ, Lee J, Chan Kim H, Kim JS. Improved Accuracy in Optical Diagnosis of Colorectal Polyps Using Convolutional Neural Networks with Visual Explanations. *Gastroenterology* 2020; **158**: 2169-2179.e8 [PMID: 32119927 DOI: 10.1053/j.gastro.2020.02.036]

37 **Urban G**, Tripathi P, Alkayali T, Mittal M, Jalali F, Karnes W, Baldi P. Deep Learning Localizes and Identifies Polyps in Real Time With 96% Accuracy in Screening Colonoscopy. *Gastroenterology* 2018; **155**: 1069-1078.e8 [PMID: 29928897 DOI: 10.1053/j.gastro.2018.06.037]

38 **Yamada M**, Saito Y, Imaoka H, Saiko M, Yamada S, Kondo H, Takamaru H, Sakamoto T, Sese J, Kuchiba A, Shibata T, Hamamoto R. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. *Sci Rep* 2019; **9**: 14465 [PMID: 31594962 DOI: 10.1038/s41598-019-50567-5]

39 **Qu J**, Hiruta N, Terai K, Nosato H, Murakawa M, Sakanashi H. Gastric Pathology Image Classification Using Stepwise Fine-Tuning for Deep Neural Networks. *J Healthc Eng* 2018; **2018**: 8961781 [PMID: 30034677 DOI: 10.1155/2018/8961781]

40 **Yoshida H**, Shimazu T, Kiyuna T, Marugame A, Yamashita Y, Cosatto E, Taniguchi H, Sekine S, Ochiai A. Automated histological classification of whole-slide images of gastric biopsy specimens. *Gastric Cancer* 2018; **21**: 249-257 [PMID: 28577229 DOI: 10.1007/s10120-017-0731-8]

41 **Mori H**, Miwa H. A histopathologic feature of the behavior of gastric signet-ring cell carcinoma; an image analysis study with deep learning. *Pathol Int* 2019; **69**: 437-439 [PMID: 31276267 DOI: 10.1111/pin.12828]

42 **Jiang Y**, Xie J, Han Z, Liu W, Xi S, Huang L, Huang W, Lin T, Zhao L, Hu Y, Yu J, Zhang Q, Li T, Cai S, Li G. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. *Clin Cancer Res* 2018; **24**: 5574-5584 [PMID: 30042208 DOI: 10.1158/1078-0432.CCR-18-0848]

43 **Van Eycke YR**, Balsat C, Verset L, Debeir O, Salmon I, Decaestecker C. Segmentation of glandular epithelium in colorectal tumours to automatically compartmentalise IHC biomarker quantification: A deep learning approach. *Med Image Anal* 2018; **49**: 35-45 [PMID: 30081241 DOI: 10.1016/j.media.2018.07.004]

44 **Graham S**, Chen H, Gamper J, Dou Q, Heng PA, Snead D, Tsang YW, Rajpoot N. MILD-Net: Minimal information loss dilated network for gland instance segmentation in colon histology images. *Med Image Anal* 2019; **52**: 199-211 [PMID: 30594772 DOI: 10.1016/j.media.2018.12.001]

45 **Abdelsamea MM**, Grineviciute RB, Besusparis J, Cham S, Pitiot A, Laurinavicius A, Ilyas M. Tumour parcellation and quantification (TuPaQ): a tool for refining biomarker analysis through rapid and automated segmentation of tumour epithelium. *Histopathology* 2019; **74**: 1045-1054 [PMID: 30735268 DOI: 10.1111/his.13838]

46 **Xu Y**, Jia Z, Wang LB, Ai Y, Zhang F, Lai M, Chang EI. Large scale tissue histopathology image classification, segmentation, and visualization via deep convolutional activation features. *BMC Bioinformatics* 2017; **18**: 281 [PMID: 28549410 DOI: 10.1186/s12859-017-1685-x]

47 **Haj-Hassan H**, Chaddad A, Harkouss Y, Desrosiers C, Toews M, Tanougast C. Classifications of Multispectral Colorectal Cancer Tissues Using Convolution Neural Network. *J Pathol Inform* 2017; **8**: 1 [PMID: 28400990 DOI: 10.4103/jpi.jpi\_47\_16]

48 **Rathore S**, Hussain M, Aksam Iftikhar M, Jalil A. Novel structural descriptors for automated colon cancer detection and grading. *Comput Methods Programs Biomed* 2015; **121**: 92-108 [PMID: 26094859 DOI: 10.1016/j.cmpb.2015.05.008]

49 **Yang K**, Zhou B, Yi F, Chen Y, Chen Y. Colorectal Cancer Diagnostic Algorithm Based on Sub-Patch Weight Color Histogram in Combination of Improved Least Squares Support Vector Machine for Pathological Image. *J Med Syst* 2019; **43**: 306 [PMID: 31410693 DOI: 10.1007/s10916-019-1429-8]

50 **Chaddad A**, Desrosiers C, Bouridane A, Toews M, Hassan L, Tanougast C. Multi Texture Analysis of Colorectal Cancer Continuum Using Multispectral Imagery. *PLoS One* 2016; **11**: e0149893 [PMID: 26901134 DOI: 10.1371/journal.pone.0149893]

51 **Yoshida H**, Yamashita Y, Shimazu T, Cosatto E, Kiyuna T, Taniguchi H, Sekine S, Ochiai A. Automated histological classification of whole slide images of colorectal biopsy specimens. *Oncotarget* 2017; **8**: 90719-90729 [PMID: 29207599 DOI: 10.18632/oncotarget.21819]

52 **Takamatsu M**, Yamamoto N, Kawachi H, Chino A, Saito S, Ueno M, Ishikawa Y, Takazawa Y, Takeuchi K. Prediction of early colorectal cancer metastasis by machine learning using digital slide images. *Comput Methods Programs Biomed* 2019; **178**: 155-161 [PMID: 31416544 DOI: 10.1016/j.cmpb.2019.06.022]

53 **Weis CA**, Kather JN, Melchers S, Al-Ahmdi H, Pollheimer MJ, Langner C, Gaiser T. Automatic evaluation of tumor budding in immunohistochemically stained colorectal carcinomas and correlation to clinical outcome. *Diagn Pathol* 2018; **13**: 64 [PMID: 30153844 DOI: 10.1186/s13000-018-0739-3]

54 **Bychkov D**, Linder N, Turkki R, Nordling S, Kovanen PE, Verrill C, Walliander M, Lundin M, Haglund C, Lundin J. Deep learning based tissue analysis predicts outcome in colorectal cancer. *Sci Rep* 2018; **8**: 3395 [PMID: 29467373 DOI: 10.1038/s41598-018-21758-3]

55 **Kather JN**, Krisam J, Charoentong P, Luedde T, Herpel E, Weis CA, Gaiser T, Marx A, Valous NA, Ferber D, Jansen L, Reyes-Aldasoro CC, Zörnig I, Jäger D, Brenner H, Chang-Claude J, Hoffmeister M, Halama N. Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. *PLoS Med* 2019; **16**: e1002730 [PMID: 30677016 DOI: 10.1371/journal.pmed.1002730]

56 **Reichling C**, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. *Gut* 2020; **69**: 681-690 [PMID: 31780575 DOI: 10.1136/gutjnl-2019-319292]

57 **Li W**, Zhang L, Tian C, Song H, Fang M, Hu C, Zang Y, Cao Y, Dai S, Wang F, Dong D, Wang R, Tian J. Prognostic value of computed tomography radiomics features in patients with gastric cancer following curative resection. *Eur Radiol* 2019; **29**: 3079-3089 [PMID: 30519931 DOI: 10.1007/s00330-018-5861-9]

58 **Zhang W**, Fang M, Dong D, Wang X, Ke X, Zhang L, Hu C, Guo L, Guan X, Zhou J, Shan X, Tian J. Development and validation of a CT-based radiomic nomogram for preoperative prediction of early recurrence in advanced gastric cancer. *Radiother Oncol* 2020; **145**: 13-20 [PMID: 31869677 DOI: 10.1016/j.radonc.2019.11.023]

59 **Li J**, Dong D, Fang M, Wang R, Tian J, Li H, Gao J. Dual-energy CT-based deep learning radiomics can improve lymph node metastasis risk prediction for gastric cancer. *Eur Radiol* 2020; **30**: 2324-2333 [PMID: 31953668 DOI: 10.1007/s00330-019-06621-x]

60 **Li Q**, Qi L, Feng QX, Liu C, Sun SW, Zhang J, Yang G, Ge YQ, Zhang YD, Liu XS. Machine Learning-Based Computational Models Derived From Large-Scale Radiographic-Radiomic Images Can Help Predict Adverse Histopathological Status of Gastric Cancer. *Clin Transl Gastroenterol* 2019; **10**: e00079 [PMID: 31577560 DOI: 10.14309/ctg.0000000000000079]

61 **Wang Y**, Liu W, Yu Y, Han W, Liu JJ, Xue HD, Lei J, Jin ZY, Yu JC. Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas. *Eur Radiol* 2020; **30**: 2934-2944 [PMID: 32020404 DOI: 10.1007/s00330-019-06629-3]

62 **Jiang Y**, Yuan Q, Lv W, Xi S, Huang W, Sun Z, Chen H, Zhao L, Liu W, Hu Y, Lu L, Ma J, Li T, Yu J, Wang Q, Li G. Radiomic signature of 18F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits. *Theranostics* 2018; **8**: 5915-5928 [PMID: 30613271 DOI: 10.7150/thno.28018]

63 **Chen W**, Wang S, Dong D, Gao X, Zhou K, Li J, Lv B, Li H, Wu X, Fang M, Tian J, Xu M. Evaluation of Lymph Node Metastasis in Advanced Gastric Cancer Using Magnetic Resonance Imaging-Based Radiomics. *Front Oncol* 2019; **9**: 1265 [PMID: 31824847 DOI: 10.3389/fonc.2019.01265]

64 **Gao Y**, Zhang ZD, Li S, Guo YT, Wu QY, Liu SH, Yang SJ, Ding L, Zhao BC, Li S, Lu Y. Deep neural network-assisted computed tomography diagnosis of metastatic lymph nodes from gastric cancer. *Chin Med J (Engl)* 2019; **132**: 2804-2811 [PMID: 31856051 DOI: 10.1097/CM9.0000000000000532]

65 **Huang Z**, Liu D, Chen X, Yu P, Wu J, Song B, Hu J, Wu B. Retrospective imaging studies of gastric cancer: Study protocol clinical trial (SPIRIT Compliant). *Medicine (Baltimore)* 2020; **99**: e19157 [PMID: 32080093 DOI: 10.1097/MD.0000000000019157]

66 **Trebeschi S**, van Griethuysen JJM, Lambregts DMJ, Lahaye MJ, Parmar C, Bakers FCH, Peters NHGM, Beets-Tan RGH, Aerts HJWL. Deep Learning for Fully-Automated Localization and Segmentation of Rectal Cancer on Multiparametric MR. *Sci Rep* 2017; **7**: 5301 [PMID: 28706185 DOI: 10.1038/s41598-017-05728-9]

67 **Wang M**, Xie P, Ran Z, Jian J, Zhang R, Xia W, Yu T, Ni C, Gu J, Gao X, Meng X. Full convolutional network based multiple side-output fusion architecture for the segmentation of rectal tumors in magnetic resonance images: A multi-vendor study. *Med Phys* 2019; **46**: 2659-2668 [PMID: 30972763 DOI: 10.1002/mp.13541]

68 **Wang J**, Lu J, Qin G, Shen L, Sun Y, Ying H, Zhang Z, Hu W. Technical Note: A deep learning-based autosegmentation of rectal tumors in MR images. *Med Phys* 2018; **45**: 2560-2564 [PMID: 29663417 DOI: 10.1002/mp.12918]

69 **Men K**, Dai J, Li Y. Automatic segmentation of the clinical target volume and organs at risk in the planning CT for rectal cancer using deep dilated convolutional neural networks. *Med Phys* 2017; **44**: 6377-6389 [PMID: 28963779 DOI: 10.1002/mp.12602]

70 **Shayesteh SP**, Alikhassi A, Fard Esfahani A, Miraie M, Geramifar P, Bitarafan-Rajabi A, Haddad P. Neo-adjuvant chemoradiotherapy response prediction using MRI based ensemble learning method in rectal cancer patients. *Phys Med* 2019; **62**: 111-119 [PMID: 31153390 DOI: 10.1016/j.ejmp.2019.03.013]

71 **Shi L**, Zhang Y, Nie K, Sun X, Niu T, Yue N, Kwong T, Chang P, Chow D, Chen JH, Su MY. Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI. *Magn Reson Imaging* 2019; **61**: 33-40 [PMID: 31059768 DOI: 10.1016/j.mri.2019.05.003]

72 **Ferrari R**, Mancini-Terracciano C, Voena C, Rengo M, Zerunian M, Ciardiello A, Grasso S, Mare' V, Paramatti R, Russomando A, Santacesaria R, Satta A, Solfaroli Camillocci E, Faccini R, Laghi A. MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer. *Eur J Radiol* 2019; **118**: 1-9 [PMID: 31439226 DOI: 10.1016/j.ejrad.2019.06.013]

73 **Bibault JE**, Giraud P, Housset M, Durdux C, Taieb J, Berger A, Coriat R, Chaussade S, Dousset B, Nordlinger B, Burgun A. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. *Sci Rep* 2018; **8**: 12611 [PMID: 30135549 DOI: 10.1038/s41598-018-30657-6]

74 **Dercle L**, Lu L, Schwartz LH, Qian M, Tejpar S, Eggleton P, Zhao B, Piessevaux H. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. *J Natl Cancer Inst* 2020; **112**: 902-912 [PMID: 32016387 DOI: 10.1093/jnci/djaa017]

75 **Ding L**, Liu GW, Zhao BC, Zhou YP, Li S, Zhang ZD, Guo YT, Li AQ, Lu Y, Yao HW, Yuan WT, Wang GY, Zhang DL, Wang L. Artificial intelligence system of faster region-based convolutional neural network surpassing senior radiologists in evaluation of metastatic lymph nodes of rectal cancer. *Chin Med J (Engl)* 2019; **132**: 379-387 [PMID: 30707177 DOI: 10.1097/CM9.0000000000000095]

76 **Taguchi N**, Oda S, Yokota Y, Yamamura S, Imuta M, Tsuchigame T, Nagayama Y, Kidoh M, Nakaura T, Shiraishi S, Funama Y, Shinriki S, Miyamoto Y, Baba H, Yamashita Y. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. *Eur J Radiol* 2019; **118**: 38-43 [PMID: 31439256 DOI: 10.1016/j.ejrad.2019.06.028]

77 **Chassagnon G**, Vakalopoulou M, Paragios N, Revel MP. Artificial intelligence applications for thoracic imaging. *Eur J Radiol* 2020; **123**: 108774 [PMID: 31841881 DOI: 10.1016/j.ejrad.2019.108774]

78 **Rudie JD**, Rauschecker AM, Bryan RN, Davatzikos C, Mohan S. Emerging Applications of Artificial Intelligence in Neuro-Oncology. *Radiology* 2019; **290**: 607-618 [PMID: 30667332 DOI: 10.1148/radiol.2018181928]

79 **Zhou LQ**, Wang JY, Yu SY, Wu GG, Wei Q, Deng YB, Wu XL, Cui XW, Dietrich CF. Artificial intelligence in medical imaging of the liver. *World J Gastroenterol* 2019; **25**: 672-682 [PMID: 30783371 DOI: 10.3748/wjg.v25.i6.672]

80 **Fave X**, Mackin D, Yang J, Zhang J, Fried D, Balter P, Followill D, Gomez D, Jones AK, Stingo F, Fontenot J, Court L. Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer? *Med Phys* 2015; **42**: 6784-6797 [PMID: 26632036 DOI: 10.1118/1.4934826]

81 **Shafiq-Ul-Hassan M**, Zhang GG, Latifi K, Ullah G, Hunt DC, Balagurunathan Y, Abdalah MA, Schabath MB, Goldgof DG, Mackin D, Court LE, Gillies RJ, Moros EG. Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. *Med Phys* 2017; **44**: 1050-1062 [PMID: 28112418 DOI: 10.1002/mp.12123]

82 **Berenguer R**, Pastor-Juan MDR, Canales-Vázquez J, Castro-García M, Villas MV, Mansilla Legorburo F, Sabater S. Radiomics of CT Features May Be Nonreproducible and Redundant: Influence of CT Acquisition Parameters. *Radiology* 2018; **288**: 407-415 [PMID: 29688159 DOI: 10.1148/radiol.2018172361]

83 **Lecler A**, Duron L, Balvay D, Savatovsky J, Bergès O, Zmuda M, Farah E, Galatoire O, Bouchouicha A, Fournier LS. Combining Multiple Magnetic Resonance Imaging Sequences Provides Independent Reproducible Radiomics Features. *Sci Rep* 2019; **9**: 2068 [PMID: 30765732 DOI: 10.1038/s41598-018-37984-8]

84 **Shiri I**, Rahmim A, Ghaffarian P, Geramifar P, Abdollahi H, Bitarafan-Rajabi A. The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. *Eur Radiol* 2017; **27**: 4498-4509 [PMID: 28567548 DOI: 10.1007/s00330-017-4859-z]

85 **Zhao B**, Tan Y, Tsai WY, Qi J, Xie C, Lu L, Schwartz LH. Reproducibility of radiomics for deciphering tumor phenotype with imaging. *Sci Rep* 2016; **6**: 23428 [PMID: 27009765 DOI: 10.1038/srep23428]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** September 19, 2020

**First decision:** October 17, 2020

**Article in press:** November 13, 2020

**Specialty type:** Gastroenterology and Hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cabezuelo AS, Gao F **S-Editor:** Wang JL **L-Editor: A P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Clinical research using artificial intelligence in gastrointestinal cancer**. Deep learning based on convolutional neural networks showing the input layer with raw data of the image, such as endoscopic, pathological, and radiological images, the hidden layer with a series of convolutions computed for each layer and the classification of the image, the prediction of malignant potentials, and the segmentation of tumor in the output layer.

**Table 1 Previous studies on upper endoscopy of gastric cancer using artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample sizes** | **Inputs** | **Tasks** | **Analysis method** | **Diagnostic performance** |
| Yoon *et al*[28] | GC (ESD/surgery) | 800 cases | GC/non-GC images in close-up and distant views | Detection and invasion depth prediction | CNN | AUC: detection, 0.981; depth, 0.851 |
| Zhu *et al*[29] | GC | 993 images | GC images | Diagnosis of invasion depth | CNN | Sensitivity: 76.4%, PPV: 89.6% |
| Li *et al*[30] | GC and healthy | 386 GC and 1702 NC images | NBI images | Diagnosis of GC | CNN | Sensitivity: 91.1%, PPV: 90.6% |
| Hirasawa *et al*[31] | GC | 13584 training and 2296 test images | GC images | Diagnosis of GC | CNN | Sensitivity: 92.2%, PPV: 30.6% |
| Ishioka *et al*[32] | EGC | 62 cases | Real-time images | Detection | CNN | Detection rate: 94.1% |
| Luo *et al*[33] | GC | 1036496 images | GC images | Detection | CNN | PPV: 0.814, NPV:0.978 |
| Horiuchi *et al*[34] | GC and gastritis | 1492 GC and 1078 gastritis images | NBI images | Detection | CNN | Sensitivity: 95.4%, PPV: 82.3% |

GC: Gastric cancer; CNN: Convolutional neural network; AUC: Area under the curve; PPV: Positive predictive value; NC: Non-cancer; NBI: Narrow-band image; EGC: Early gastric cancer.

**Table 2 Previous studies on colonoscopy using artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample sizes** | **Inputs** | **Tasks** | **Analysis method** | **Diagnostic performance** |
| Akbari *et al*[35] | Screening endoscopy | 300 polyp images | Polyp images | Auto segmentation of polyps | CNN | Accuracy: 0.977, Sensitivity: 74.8% |
| Jin *et al*[36] | Screening endoscopy | Training: 2150 polyps, test: 300 polyps | NBI images | Differentiation of adenoma and hyperplastic polyps | CNN | The model reduced the time of endoscopy and increased accuracy by novice endoscopists |
| Urban *et al*[37] | Screening endoscopy | 8641 polyp images and 20 colonoscopy videos | Polyp images | Detection of polyps | CNN | AUC: 0.991, Accuracy: 96.4% |
| Yamada *et al*[38] | Screening endoscopy | 4840 images, 77 colonoscopy videos | Real-time  images | Differentiation of the early signs of CRC | CNN | Sensitivity: 97.3%, Specificity: 99.0% |

CNN: Convolutional neural network; NBI: Narrow-band image; AUC: Area under the curve.

**Table 3 Previous studies on the pathology of gastric cancer using artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample size** | **Input** | **Task** | **Analysis method** | **Diagnostic performance** |
| Qu *et al*[39] | GC | 15000 images | Pathological images | Evaluation of stepwise methods | CNN | AUC: 0828-0.920 |
| Yoshida *et al*[40] | GC | 3062 biopsy samples | Pathological images stained by H&E | Automatic segmentation,  diagnosis of carcinoma | CNN | Sensitivity: 89.5%, specificity: 50.7% |
| Mori *et al*[41] | GC (surgery) | 516 images from 10 GC cases | Pathological images stained by H&E | Diagnosis of invasion depth in signet cell carcinoma | CNN | Sensitivity: 90%, Specificity: 81% |
| Jiang *et al*[42] | GC (surgery) | 786 cases | IHC (CD3, CD8, CD45RO, CD45RA, CD57, CD68, CD66b, and CD34) | Prediction of survival | SVM | The immunomarker SVM was useful for predicting survival |

GC: Gastric cancer; AUC: Area under the curve; H&E: Hematoxylin eosin staining; CNN: Convolutional neural network; IHC: Immunohistochemistry; SVM: Support vector machine.

**Table 4 Previous studies on the pathology of colorectal cancer using artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample size** | **Input** | **Task** | **Analysis method** | **Diagnostic performance** |
| Van Eycke *et al*[43] | CRC |  | H&E staining, IHC image | Segmentation of the glandular epithelium | TMA, CNN | F1 value: 0,912 |
| Graham *et al*[44] | CRC |  | H&E staining | Differentiation of intratumor glands | CNN | F1 values: 0.90 |
| Abdelsamea *et al*[45] | CRC | 333 samples | H&E staining, IHC (CD3) | Differentiation of the tumor epithelium | TMA, CNN | Accuracy: 0.93-0.94 |
| Yan *et al*[46] | CRC |  | H&E staining | Tumor classification,  segmentation of tumors, | CNN | Accuracy: classification, 97.8%; segmentation, 84% |
| Haj-Hassan *et al*[47] | CRC |  | Multispectral images | Segmentation of carcinoma | CNN | Accuracy: 99.1% |
| Rathore *et al*[48] | CRC | Biopsy samples | H&E staining | Detection and grading of tumors | Texture and morphology patterns, SVM | Recognition rate: detection, 95.4%; grading; 93.4% |
| Yang *et al*[49] | CRC | 180 samples | H&E staining | Diagnosis of benign tumors, neoplasms, and carcinoma | SVM, histogram, texture | AUC: 0.852 |
| Chaddad *et al*[50] | CRC | 30 cases | H&E staining | Diagnosis of carcinoma, adenoma, and benign tumors | Automatic segmentation, texture | Accuracy: 98.9% |
| Yoshida *et al*[51] | CRC | 1328 samples | H&E staining | Diagnosis of benign tumors, neoplasms, and carcinoma | CNN, automatic analysis of structure | Undetected rate of carcinoma and adenoma: 0-9.3% and 0-9.9%, respectively |
| Takamatsu *et al*[52] | CRC surgery | 397 samples | H&E staining | Prediction of lymph node metastasis | LR, shape analysis | AUC: 0.94 |
| Weis *et al*[53] | CRC | 596 cases | IHC (AE1/AE3) | Automatic evaluation of tumor budding | TMA, CNN | Correlation; R2 value: 0.86 |
| Bychkov *et al*[54] | CRC surgery | 420 cases | H&E staining | Prediction of survival | TMA, CNN | Good biomarker for predicting survival |
| Kather *et al*[55] | CRC | 973 slides | H&E staining | Prediction of survival | Stromal pattern, CNN | Good biomarker for predicting survival |
| Reichling *et al*[56] | CRC surgery | 1018 cases | HE, IHC (CD3, CD8) | Prediction of survival | RF, monogram | Good biomarker for predicting survival |

CRC: Colorectal cancer; H&E: Hematoxylin eosin staining; IHC: Immunohistochemistry; TMA: Tissue microarray; CNN: Convolutional neural network; SVM: Support vector machine; AUC: Area under the curve; LR: Linear regression.

**Table 5 Previous studies on the radiological diagnosis of gastric cancer using radiomics or artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample size** | **Input** | **Task** | **Analysis method** | **Diagnostic performance** |
| Li *et al*[57] | GC, radical surgery | 181 cases | Primary tumor, preoperative CT | Prediction of survival | Manual segmentation, radiomics, Nomograms | The TNM stage and radiomics signature were good biomarkers |
| Zhang *et al*[58] | GC, radical surgery | 669 cases | Primary tumor, preoperative CT | Predication of early recurrence | Manual segmentation, radiomics, Nomograms | AUC: 0.806-0.831 |
| Li *et al*[59] | GC, radical surgery | 204 cases | Primary tumor, pre-operative dual-energy CT | Pre-operative diagnosis of LNM | Manual segmentation, radiomics, Nomogram | AUC; 0.82--.84 |
| Li *et al*[60] | GC, radical surgery | 554 cases | Primary tumor, preoperative CT | Prediction of a pathological status, survival | Semi-automatic segmentation, radiomics | AUC for prediction of the pathological status: 0.77, the TNM stage and radiomics signature were good biomarkers |
| Wang *et al*[61] | GC, radical surgery | 187 cases | Primary tumor, preoperative dynamic CT | Pre-operative prediction of intestinal-type GC | Manual segmentation, radiomics, Nomograms | AUC: 0.904 |
| Jiang *et al*[62] | GC, surgery | 214 cases | Primary tumor, preoperative PET-CT | Prediction of survival | Manual segmentation, radiomics, Nomograms | C-index: DFS, 0.800; OS, 0.786 |
| Chen *et al*[63] | GC, surgery | 146 cases | Primary tumor, preoperative MRI | Pre-operative diagnosis of lymph node metastasis | Manual segmentation, radiomics analysis | AUC: 0.878 |
| Gao *et al*[64] | GC, surgery | 627 cases, 17340 images | Lymph nodes, preoperative CT | Pre-operative diagnosis of lymph node metastasis | Manual segmentation, deep learning | AUC: 0.9541. |
| Huang *et al*[65] | GC, surgery |  | Primary tumor, preoperative CT | Pre-operative diagnosis of peritoneal metastasis | Manual segmentation, CNN | Ongoing, retrospective cross-sectional study |

GC: Gastric cancer; CT: Computed tomography; AUC: Area under the curve; LNM: Lymph node metastasis; DFS: Disease-free survival; MRI: Magnetic resonance imaging; CNN: Convolutional neural network.

**Table 6 Previous studies on the radiological diagnosis of colorectal cancer using radiomics or artificial intelligence**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Targets** | **Sample size** | **Input** | **Task** | **Analysis method** | **Diagnostic performance** |
| Trebeschi *et al*[66] | LRC | 140 cases | Primary tumor, MRI | Automatic detection, segmentation | CNN | DSC: 0.68-0.70, AUC: 0.99 |
| Wang *et al*[67] | LRC | 568 cases | Primary tumor, MRI | Automatic segmentation | CNN | DSC: 0.82 |
| Wang *et al*[68] | LRC | 93 cases | Primary tumor, MRI | Automatic segmentation | Deep learning | DSC: 0.74 |
| Men *et al*[69] | LRC | 278 cases | Primary tumor, CT | Automatic segmentation | CNN | DSC: 0.87 |
| Shayesteh *et al*[70] | LRC, NCRT followed by surgery | 98 cases | Primary tumor, pre-treatment MRI | Prediction of CRT responses | Manual segmentation, radiomics, machine learning | AUC: 0.90 |
| Shi *et al*[71] | LRC, NCRT followed by surgery | 45 cases | Primary tumor, pre-treatment MRI, mid-radiation MRI | Prediction of CRT responses | Manual segmentation, CNN | AUC: CR, 0.83; good response, 0.93 |
| Ferrari *et al*[72] | LRC, NCRT followed by surgery | 55 cases | Primary tumor, MRI before, during and after CRT | Prediction of CRT responses | Manual segmentation, radiomics, RF | AUC: CR: 0.86, non-response: 0.83 |
| Bibault *et al*[73] | LRC, NCRT followed by surgery | 95 cases | Primary tumor, pre-operative CT | Prediction of CRT responses | Manual segmentation, radiomics, CNN | 80% accuracy |
| Dercle *et al*[74] | CRC, FOLFILI with/without cetuximab | 667 cases | Metastatic tumor, CT | Prediction of tumor sensitivity to chemotherapy | Manual segmentation, radiomics, machine learning | AUC: 0.72-0.80 |
| Ding *et al*[75] | LRC, radical surgery | 414 cases | Lymph nodes, pre-operative MRI | Pre-operative diagnosis of lymph node metastasis | Manual segmentation, CNN | AI system > radiologist |
| Taguchi *et al*[76] | CRC | 40 cases | Primary tumor, CT | Prediction of the KRAS status | Manual segmentation, radiomics | AUC: 0.82 |

LRC: Lower rectal cancer; MRI: Magnetic resonance imaging; CNN: Convolutional neural network; DSC: Dice similarity coefficient; AUC: Area under the curve; NCRT: Neoadjuvant chemoradiotherapy; CR: Complete response; RF: Random forest; CT: Computed tomography; CRC: Colorectal cancer.